New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1

Molecular Pharmacology

Volumn 86, Issue 3, 2014, Pages 342-357

  Coleman, Nichole ^a   Brown, Brandon M ^a   Oliván Viguera, Aida ^c   Singh, Vikrant ^a   Olmstead, Marilyn M ^b   Valero, Marta Sofia ^d   Köhler, Ralf ^c   Wulff, Heike ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^d UNIVERSIDAD SAN JORGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLNAPHTHO[1,2 D]THIAZOL 2 AMINE; 5 METHYLNAPHTHO[2,1 D]OXAZOL 2 AMINE; BENZOTHIAZOLE; BENZOTHIAZOLE DERIVATIVE; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; POTASSIUM CHANNEL KV1.3; POTASSIUM CHANNEL KV11.1; POTASSIUM CHANNEL KV2.1; POTASSIUM CHANNEL KV3.1; SKA 111; SKA 121; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; SODIUM CHANNEL NAV1.2; SODIUM CHANNEL NAV1.4; SODIUM CHANNEL NAV1.5; SODIUM CHANNEL NAV1.7; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; 5 METHYLNAPHTHO(2,1 D)OXAZOL 2 AMINE; 5-METHYLNAPHTHO(2,1-D)OXAZOL-2-AMINE; BRADYKININ; KCNN4 PROTEIN, HUMAN; NAPHTHO(1,2 D)THIAZOL 2 YLAMINE; NAPHTHO(1,2-D)THIAZOL-2-YLAMINE; OXAZOLE DERIVATIVE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; HEART RATE; HUMAN; HUMAN CELL; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; WILD TYPE; ANIMAL; BLOOD PRESSURE; C57BL MOUSE; CHANNEL GATING; CHEMISTRY; CHLOROCEBUS AETHIOPS; CORONARY BLOOD VESSEL; COS 1 CELL LINE; GENETICS; HEK293 CELL LINE; METABOLISM; MUSCLE ISOMETRIC CONTRACTION; PHYSIOLOGY; SWINE; VASCULAR SMOOTH MUSCLE; X RAY CRYSTALLOGRAPHY;

ANIMALS; BENZOTHIAZOLES; BLOOD PRESSURE; BRADYKININ; CERCOPITHECUS AETHIOPS; CORONARY VESSELS; COS CELLS; CRYSTALLOGRAPHY, X-RAY; HEK293 CELLS; HUMANS; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; ION CHANNEL GATING; ISOMETRIC CONTRACTION; MALE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; OXAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; VASODILATOR AGENTS;

EID: 84906308946     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.093286     Document Type: Article

References (51)

1. + channels: form and function. Annu Rev Physiol 74:245-269.
2. +) channels: a novel target for medicinal chemistry efforts? ChemMedChem 7:1741-1755.
3. + channel SK3 generates age-related memory and LTP deficits. Nat Neurosci 6:911-912.
4. Brähler S, Kaistha A, Schmidt VJ, Wölfle SE, Busch C, Kaistha BP, Kacik M, Hasenau AL, Grgic I, and Si H et al. (2009) Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 119:2323-2332.
5. Brown BM, Coleman N, Oliván-Viguera A, Köhler R, Wulff H (2014) Positive KCa channel gating modulators with selectivity for KCa3.1. FASEB J 28:1057.6.
6. + channels. J Gen Physiol 130:601-610.
7. + channels. J Neurosci 22:6499-6506.
8. Dalsgaard T, Kroigaard C, and Simonsen U (2010) Calcium-activated potassium channels - a therapeutic target for modulating nitric oxide in cardiovascular disease? Expert Opin Ther Targets 14:825-837.
9. Damkjaer M, Nielsen G, Bodendiek S, Staehr M, Gramsbergen JB, de Wit C, Jensen BL, Simonsen U, Bie P, and Wulff H et al. (2012) Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs. Br J Pharmacol 165:223-234.
10. Debono MW, Le Guern J, Canton T, Doble A, and Pradier L (1993) Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 235:283-289. (Pubitemid 23130445)
11. + channel. Am J Physiol 271:L775-L784.
12. +) channels TREK-1 and TRAAK. Mol Pharmacol 57:906-912.
13. Edwards G, Félétou M, and Weston AH (2010) Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflugers Arch 459:863 -879.
14. Fanger CM, Ghanshani S, Logsdon NJ, Rauer H, Kalman K, Zhou J, Beckingham K, Chandy KG, Cahalan MD, and Aiyar J (1999) Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa channel, IKCa1. J Biol Chem 274:5746-5754. (Pubitemid 29109229)
15. 2+. J Biol Chem 284:389-403.
16. Garneau L, Klein H, Lavoie MF, Brochiero E, Parent L, and Sauvé R (2014) Aromatic-aromatic interactions between residues in KCa3.1 pore helix and S5 transmembrane segment control the channel gating process. J Gen Physiol 143:289-307.
17. + channel, hIK1, is conferred by a C-terminal domain. J Biol Chem 276:10963-10970.
18. Göblyös A, Santiago SN, Pietra D, Mulder-Krieger T, von Frijtag Drabbe Künzel J, Brussee J, and Ijzerman AP (2005) Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors. Lack of effect of 2-aminothiazoles as allosteric enhancers. Bioorg Med Chem 13:2079-2087. (Pubitemid 40261128)
19. Grgic I, Kaistha BP, Hoyer J, and Köhler R (2009) Endothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses: relevance to cardiovascular pathologies and drug discovery. Br J Pharmacol 157:509-526.
20. + channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45:1227-1234.
21. Grunnet M, Jespersen T, Angelo K, Frøkjaer-Jensen C, Klaerke DA, Olesen SP, and Jensen BS (2001) Pharmacological modulation of SK3 channels. Neuropharmacology 40:879-887. (Pubitemid 32510801)
22. + channels. Br J Pharmacol 151:655-665.
23. Hougaard C, Hammami S, Eriksen BL, Sørensen US, Jensen ML, Strøbæk D, and Christophersen P (2012) Evidence for a common pharmacological interaction site on K(Ca)2 channels providing both selective activation and selective inhibition of the human K(Ca)2.1 subtype. Mol Pharmacol 81:210-219.
24. + channels by 4-(2-methoxyphenylcarbamoyloxymethyl)- piperidine-1-carboxylic acid tert-butyl ester (GW542573X) is dependent on serine 293 in the S5 segment. Mol Pharmacol 76:569-578.
25. Jenkins DP, Yu W, Brown BM, Løjkner LD, and Wulff H (2013) Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators. Assay Drug Dev Technol 11:551-560.
26. Joiner WJ, Wang LY, Tang MD, and Kaczmarek LK (1997) hSK4, a member of a novel subfamily of calcium-activated potassium channels. Proc Natl Acad Sci USA 94:11013-11018. (Pubitemid 27430852)
27. 2-terminal multi-basic RKR motif is required for the ATP-dependent regulation of hIK1. Channels (Austin) 1:80-91.
28. Jordan AD, Luo C, and Reitz AB (2003) Efficient conversion of substituted aryl thioureas to 2-aminobenzothiazoles using benzyltrimethylammonium tribromide. J Org Chem 68:8693-8696. (Pubitemid 37329133)
29. Kasumu AW, Hougaard C, Rode F, Jacobsen TA, Sabatier JM, Eriksen BL, Strøbæk D, Liang X, Egorova P, and Vorontsova D et al. (2012) Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem Biol 19:1340-1353.
30. Klein H, Garneau L, Banderali U, Simoes M, Parent L, and Sauvé R (2007) Structural determinants of the closed KCa3.1 channel pore in relation to channel gating: results from a substituted cysteine accessibility analysis. J Gen Physiol 129:299-315. (Pubitemid 46506981)
31. Köhler M, Hirschberg B, Bond CT, Kinzie JM, Marrion NV, Maylie J, and Adelman JP (1996) Small-conductance, calcium-activated potassium channels from mammalian brain. Science 273:1709-1714. (Pubitemid 26317786)
32. Köhler R (2012) Cardiovascular alterations in KCa3.1/KCa2.3- deficient mice and after acute treatment with KCa3.1/KCa2.3 activators. EDHF 2012: 10th Anniversary Meeting June 27th-30th, 2012; Feletou M, Vanhoutte PM (eds) vol. 49, pp 1-54 Vaux-de-Cernay, France.
33. Köhler R, Kaistha BP, and Wulff H (2010) Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. Expert Opin Ther Targets 14:143-155.
34. Li W, Halling DB, Hall AW, and Aldrich RW (2009) EF hands at the N-lobe of calmodulin are required for both SK channel gating and stable SK-calmodulin interaction. J Gen Physiol 134:281-293.
35. Ng KF, Leung SW, Man RY, and Vanhoutte PM (2008) Endothelium-derived hyperpolarizing factor mediated relaxations in pig coronary arteries do not involve Gi/o proteins. Acta Pharmacol Sin 29:1419-1424.
36. + channels. J Biol Chem 276:9762-9769.
37. Radtke J, Schmidt K, Wulff H, Köhler R, and de Wit C (2013) Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice. Br J Pharmacol 170:293-303.
38. Rosa JC, Galanakis D, Ganellin CR, Dunn PM, and Jenkinson DH (1998) Bis-quinolinium cyclophanes: 6,10-diaza-3(1,3),8(1,4)-dibenzena-1,5(1,4)- diquinolinacyclodecaphane (UCL 1684), the first nanomolar, non-peptidic blocker of the apamin-sensitive Ca(2+)-activated K+ channel. J Med Chem 41:2-5. (Pubitemid 128719272)
39. Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Köhler R, and Wulff H (2009) Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 75:281-295.
40. Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hänsel W, and Wulff H (2005) Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 68:1254-1270. (Pubitemid 41539982)
41. Schuart J and Müller HK (1973) [2-Aminooxazoles and 2-iminooxazolines. 1: reaction of racemic alpha-methylaminopropiophenone using cyanobromide]. Pharmazie 28:438-439.
42. Sheldrick GM (2008) A short history of SHELX. Acta Crystallogr A 64:112-122.
43. Singh S, Syme CA, Singh AK, Devor DC, and Bridges RJ (2001) Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 296:600-611. (Pubitemid 32112491)
44. + channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime). Biochim Biophys Acta 1665:1-5.
45. Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, and Wulff H (2005) International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev 57:463-472. (Pubitemid 43036436)
46. Wulff H and Köhler R (2013) Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets. J Cardiovasc Pharmacol 61:102-112.
47. + channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci USA 97:8151-8156.
48. + channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev 108:1744-1773.
49. Xia XM, Fakler B, Rivard A, Wayman G, Johnson-Pais T, Keen JE, Ishii T, Hirschberg B, Bond CT, and Lutsenko S et al. (1998) Mechanism of calcium gating in small-conductance calcium-activated potassium channels. Nature 395:503-507. (Pubitemid 28462445)
50. 2+-activated potassium channels. Nat Commun 3:1021.
51. 2+-sensing and SK channel activation. Proc Natl Acad Sci USA 110:4828-4833.